Exela Pharma Sciences recalls ibuprofen lysine injection vials

Tim Casey | | Cardiovascular Business | Interventional Cardiology

Exela Pharma Sciences, LLC voluntarily recalled a lot of its ibuprofen lysine injection vials after discovering some of the vials contained particulate matter.

The FDA announced the recall in a news release on Feb. 8.

Ibuprofen lysine injection is used to close a clinically significant patent ductus arteriosus in premature infants when medical management is ineffective.

Exela and marketer X-Gen Pharmaceuticals have received no adverse event reports related to the recall. However, the companies said that participate matter could block blood vessels, provoke an immune reaction and/or lead to potentially life threatening microinfarcts.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Related Content

First patient treated with transcatheter heart failure device to reduce LV size
Angiographic catheters recalled due to safety risk
TAVR patients with moderate or greater TR may face increased risks
Robotic heart surgery represents a key step forward for SS Innovations
Late-breaking clinical trials announced for New York Valves 2025
Next-day discharge after TAVR is still safe when alternative access is required

Around the web

Health Exec
Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging
Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business
U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.